Premium
Antigens and Antibodies in Disease With Specifics About CGRP Immunology
Author(s) -
Taylor Frederick R.
Publication year - 2018
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/head.13409
Subject(s) - calcitonin gene related peptide , monoclonal antibody , medicine , receptor , immunology , antigen , migraine , calcitonin , pharmacology , antibody , neuropeptide
Growth in knowledge about calcitonin gene‐related peptide (CGRP) in the pathophysiology of migraine brought CGRP antagonism to headache medicine. Failures in development of small molecule CGRP receptor antagonists and increasing knowledge and use of monoclonal antibodies (mAbs) in medicine led to the breakthrough development of large molecule anti‐CGRP mAbs: eptinezumab, erenumab, fremanezumab, and galcanezumab. This specifics about CGRP immunology aims to outline: (1) knowledge needed for CGRP antagonism and (2) developmental issues of specific CGRP antagonists for provider use. This clinically oriented review documents IgG structure and function; state of the art of monoclonal IgG production and ligand‐antigen‐antibodies in migraine therapeutics contributing to immunogenic risks and off‐target toxicities. Specifics to CGRP ligand, receptor, antagonism, and molecules, small and large, complete this review. Completion will facilitate assessment of the similarities, differences, and application of the forthcoming anti‐CGRP receptor and ligand antagonists for patients.